Suzhou, China and Cambridge, Massachusetts, USA, October 18th, 2024 - MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces the appointment of Bruce Chabner, M.D., as Senior Strategic Advisor. Dr. Chabner will serve as a key Scientific Advisory Board member to the MediLink leadership team and bring his significant expertise in medical oncology to help strengthen MediLink’s global development efforts on its next-generation antibody drug conjugate pipelines.“I am thrilled to welcome Dr. Bruce Chabner to our team,” said Dr Tony Tongtong Xue, CEO of MediLink. “Bruce is one of the most renowned oncologists in the world, and his decades of experience and profound scientific insights will undoubtedly propel our pipeline of innovative ADCs to new heights. Dr. Chabner's appointment comes at a pivotal time for MediLink as we strive to bring transformative therapies to global patients in need.Bruce A. Chabner, M. D., is the Clinical Director, Emeritus, of the Massachusetts General Hospital (MGH) Cancer Center and a Professor of Medicine at Harvard Medical School. He is a graduate of Yale College and Harvard Medical School. Dr. Chabner trained in medical oncology under Vincent De Vita at the National Cancer Institute and in the biochemical pharmacology laboratory of Joseph Bertino at Yale, following which he returned to the National Cancer Institute in 1971, where he became the Director of the Clinical Oncology Program in 1975 and served as the Director of the NCI Division of Cancer Treatment from 1982 to 1995. In that capacity he was responsible for the development of paclitaxel, cisplatin, and a number of other cancer drugs. In 1995 he joined MGH as Chief of the Division of Hematology and Medical Oncology and Clinical Director of the MGH Cancer Center, in which capacity he served for 12 years, building a faculty and research program that was instrumental in developing targeted drugs for non-small cell cancer and other solid tumors. He was one of the founding scientific directors of the Dana Farber/Harvard Cancer Center grant, first awarded in 2000 and has since led and participated in its Developmental Therapeutics program. He led fellowship programs for medical oncology training for four decades and was responsible for the training of many of the current and past leaders in translational and clinical cancer research in the US and abroad.
MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs with global competitiveness. MediLink has developed its proprietary TMALIN® ADC technology platform, enabling the generation of homogeneous ADC with high drug-antibody ratio and improved therapeutic window for the treatment of solid tumors. MediLink aims to provide improved treatment options for global patients and address unmet medical needs. The company is headquartered in Suzhou, China and has established R&D sites in Shanghai, China and Boston, US.
